In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Year

    Select Year(s)

  • Session Type

    Select Session Type(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Boehringer Ingelheim

89 results for your search

2018

Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent PCI.

Congress : ESC Congress 2018

  • Session : Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent percutaneous coronary intervention
  • Speaker : C P Cannon (Boston,US), J M Ten Berg (Nieuwegein,NL)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Comprehensive patient care: from OAC choice to post-PCI (and beyond).

Congress : ESC Congress 2018

  • Session : Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
  • Speaker : G Nickenig (Bonn,DE)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Discussion and close: anticoagulation in atrial fibrillation and beyond.

Congress : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : J Halperin (New York,US), G Y H Lip (Birmingham,GB)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Does OAC reversal matter to your cardiac patients?

Congress : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : C Pollack (Philadelphia,US)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Dual vs triple therapy in atrial fibrillation post-PCI: how has the story evolved?

Congress : ESC Congress 2018

  • Session : Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
  • Speaker : C P Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

GLORIA-AF: latest results from this prospective study.

Congress : ESC Congress 2018

  • Session : Anticoagulation and your atrial fibrillation patients: bringing it all together in clinical practice
  • Speaker : G Y H Lip (Birmingham,GB)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Improving care decisions in patients with atrial fibrillation: panel discussion and Q&A.

Congress : ESC Congress 2018

  • Session : Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
  • Speaker : C P Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Latest developments for dual vs triple antithrombotic therapy post-PCI.

Congress : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : G Y H Lip (Birmingham,GB)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

Latest developments for uninterrupted anticoagulation in atrial fibrillation ablation.

Congress : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : S Willems (Hamburg,DE)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access
2018

NOACs and reversal: let's discuss our clinical experience.

Congress : ESC Congress 2018

  • Session : NOACs and reversal: let's discuss our clinical experience
  • Speaker : JW Eikelboom (Hamilton,CA), A Tomaszuk-Kazberuk (Bialystok,PL)
  • Sponsored by Boehringer Ingelheim

Some member-only content

days left for free access

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are